Open AccessPredicting efficacy of dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes: Association of glycated hemoglobin reduction with serum eicosapentaenoic acid and docosahexaenoic acid levels
Author(s) -
Iwasaki Masahiro,
Hoshian Fuminori,
Tsuji Tomoko,
Hirose Naoki,
Matsumoto Tomoko,
Kitatani Naomi,
Sugawara Kenji,
Usui Ryota,
Kuwata Hitoshi,
Sugizaki Kazu,
Kitamoto Yuka,
Fujiwara Shuichi,
Watanabe Koin,
Hyo Takanori,
Kurose Takeshi,
Seino Yutaka,
Yabe Daisuke
Publication year - 2012
Publication title -
journal of diabetes investigation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.089
H-Index - 50
eISSN - 2040-1124
pISSN - 2040-1116
DOI - 10.1111/j.2040-1124.2012.00214.x
Subject(s) - vildagliptin , alogliptin , medicine , sitagliptin , type 2 diabetes , docosahexaenoic acid , eicosapentaenoic acid , glycated hemoglobin , endocrinology , diabetes mellitus , dipeptidyl peptidase 4 , hemoglobin , dipeptidyl peptidase 4 inhibitor , gastroenterology , polyunsaturated fatty acid , fatty acid , biochemistry , chemistry
This study was initiated to identify clinical and dietary parameters that predict efficacy of dipeptidyl peptidase‐4 inhibitors. A total of 72 untreated Japanese patients with type 2 diabetes who received DPP‐4 inhibitors (sitagliptin, alogliptin or vildagliptin) for 4 months were examined for changes of glycated hemoglobin (HbA 1c ) and body mass index (BMI), and self‐administered 3‐day food records, as well as serum levels of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). DPP‐4 inhibitors significantly reduced HbA 1c (before initiation of DPP‐4 inhibitors 7.2 ± 0.7%, 4 months after initiation of DPP‐4 inhibitors 6.7 ± 0.6% [paired t ‐test, P < 0.01 vs before]). Multiple regression analysis showed that changes of HbA 1c were significantly correlated with baseline HbA 1c, as well as estimated intake of fish. Furthermore, changes of HbA 1c were significantly correlated with serum levels of EPA ( r = −0.624, P < 0.01) and DHA ( r = −0.577, P < 0.01). HbA 1c reduction by DPP‐4 inhibitors is significantly correlated with estimated intake of fish and serum levels of EPA and DHA. (J Diabetes Invest, doi: 10.1111/j.2040‐1124.2012.00214.x, 2012)